The GAIA (CLL13) study assessed the effectiveness and safety of three frontline treatments consisting of venetoclax (BCL2 inhibitor) combined with CD20 antibody compared to standard CIT for patients with CLL who were fit and without the TP53 mutation/deletion. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.